Abstract
138P Cost-effectiveness of nivolumab and ipilimumab versus chemotherapy (with and without bevacizumab) in patients with unresectable malignant pleural mesothelioma in Switzerland
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have